Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
14 November 2014Website:
http://www.fibrogen.comNext earnings report:
06 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 23:28:03 GMTDividend
Analysts recommendations
Institutional Ownership
FGEN Latest News
FibroGen, Inc. (NASDAQ:FGEN ) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants David DeLucia - CFA Vice President, Corporate FP&A & Investor Relations Thane Wettig - Chief Executive Officer Deyaa Adib - Chief Medical Officer Juan Graham - Chief Financial Officer Chris Chung - Senior Vice President, China Operations Conference Call Participants Dalton Greenwood - William Blair Dina Ramadane - Bank of America Paul Choi - Goldman Sachs Operator Good day and welcome to the FibroGen Second Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.
FibroGen (FGEN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.65 per share a year ago.
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate FibroGen's immuno-oncology assets, FG-3165 and FG-3175, in combination with Regeneron's anti-PD-1 therapy, LIBTAYO® (cemiplimab), in patients with solid tumors.
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) of FG-3165, a galectin-9 (Gal9) targeted monoclonal antibody under development for treatment of solid tumors characterized by high Gal9 levels of expression.
SAN FRANCISCO, May 23, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced positive interim results from the dose escalation portion of the investigator-sponsored Phase 1b/2 study conducted by the University of California San Francisco of FG-3246 (FOR46), a potential first-in-class anti-CD46 antibody drug conjugate (ADC) with a MMAE-containing payload, in combination with enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Stocks are at the mercy of many factors, and often, prices are just a poor earnings report or a negative headline away from a significant drop. There are times when nobody has any way of preparing.
FibroGen, Inc. (FGEN) Q3 2023 Earnings Call Transcript
The headline numbers for FibroGen (FGEN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
While a contentious topic, investors seeking long-term success must frequently consider stocks to sell. Similar to changing the oil in a combustion-powered car, you've got to keep the overall machinery running well.
FibroGen Inc (NASDAQ:FGEN) plummeted some 27% lower in Wednesday's early deals after revealing that its intended treatment for Duchenne muscular dystrophy failed to achieve primary and secondary endpoints in a clinical study. In the trial, the potential drug, pamrevlumab, had targeted an improvement in an ambulatory assessment score at 52 weeks in boys with DMD, ages six through 11.
- 1(current)
- 2
What type of business is FibroGen?
FibroGen, Inc. is a biopharmaceutical company that discovers, develops, and commercializes a range of innovative therapeutic products for the treatment of anemia, fibrotic diseases, and cancer. The company was founded in 1993. Its corporate and research divisions are located in San Francisco, California. FibroGen Inc. has two leading clinical development candidates: Roxadustat - used in the treatment of anemia in chronic kidney disease, myelodysplastic syndromes, and anemia induced by chemotherapy. Pamrevlumab - for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy. None of the company's products have reached the stage of commercial sales.
What sector is FibroGen in?
FibroGen is in the Healthcare sector
What industry is FibroGen in?
FibroGen is in the Biotechnology industry
What country is FibroGen from?
FibroGen is headquartered in United States
When did FibroGen go public?
FibroGen initial public offering (IPO) was on 14 November 2014
What is FibroGen website?
https://www.fibrogen.com
Is FibroGen in the S&P 500?
No, FibroGen is not included in the S&P 500 index
Is FibroGen in the NASDAQ 100?
No, FibroGen is not included in the NASDAQ 100 index
Is FibroGen in the Dow Jones?
No, FibroGen is not included in the Dow Jones index
When was FibroGen the previous earnings report?
No data
When does FibroGen earnings report?
The next expected earnings date for FibroGen is 06 November 2024